MAPP Goes South

How sensitive is the stock market to bad news?  Map Pharmaceuticals Inc.(NasdaqGM: MAPP) announced on Feb. 23 (here) that a clinical trial of a children’s asthma drug didn’t perform any better than a placebo.  Shares have fallen 82% since.


This entry was posted on Wednesday, February 25th, 2009 at 5:17 pm and is filed under Pharmaceutical and Biotech. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply